Milestone Scientific Financials - Benzinga

Milestone Scientific Inc

MLSSAMEX

Trade with Public

Trade with Public

$0.5530

0.02384.5%

At close: Aug 13, 5:00 PM EST

Earnings: Q2 2026 earnings were released today after the market close

Conference Call: Conference call scheduled tomorrow at 8:30 AM

Click to view the webcast

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Milestone Scientific Financials

Milestone Scientific (MLSS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Milestone Scientific Q2 EPS $(0.01), Inline, Sales $2.841M Beat $2.700M Estimate

Milestone Scientific (AMEX:MLSS) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.

Benzinga Newsdesk

PRO
Milestone Scientific Expects Q2 Revenue Of ~$2.8M, Up 21% YoY; H1 Revenue Of ~$5M, Up 9% YoY

Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced preliminary, unaudited revenue for the second quarter

Benzinga Newsdesk

PRO
Reported earlier, Milestone Scientific Affirms FY2026 Sales Guidance of $9.800M-$10.200M vs $9.910M Est

Milestone Scientific (AMEX:MLSS) affirms FY2026 sales outlook from $9.800 million-$10.200 million to $9.800 million-$10.200 million vs $9.910 million estimate.

Benzinga Newsdesk

PRO
Milestone Scientific Q1 EPS $(0.01), Inline, Sales $2.162M Miss $2.252M Estimate

Milestone Scientific (AMEX:MLSS) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.

Benzinga Newsdesk

Earnings Scheduled For May 13, 2026

Benzinga Insights

PRO
Milestone Scientific Sees FY2026 Sales $9.800M-$10.200M vs $9.910M Est

Milestone Scientific (AMEX:MLSS) sees FY2026 sales of $9.800 million-$10.200 million vs $9.910 million analyst estimate.

Benzinga Newsdesk